Cx43 and GJA1-20k overexpression effects on mitochondrial transfer

PRIMARY OUTCOME

increased mitochondrial transfer with Cx43 overexpression

EXPECTED OUTCOMES

1. Cx43-overexpressing MSCs will show a **2.5-3.5× increase** in mitochondrial transfer to chondrocytes compared to empty vector controls, as measured by MitoTracker signal intensity per chondrocyte (Cx43-OE: 847 ± 124 AU vs. empty vector: 254 ± 67 AU, mean ± SD, p < 0.001). 2. GJA1-20k overexpression will produce a **1.8-2.4× increase** in mitochondrial transfer relative to empty vector, demonstrating partial but significant rescue compared to full-length Cx43 (GJA1-20k-OE: 457 ± 89 AU, p < 0.01 vs. empty vector). 3. Gap junction intercellular communication (GJIC) assay will show **4.2 ± 0.6× higher** dye transfer rate in Cx43-OE cells vs. empty vector, confirming functional gap junction formation drives the enhanced mitochondrial transfer. 4. Chondrocyte viability will improve by **35-45%** in IL-1β-treated co-cultures with Cx43-OE MSCs compared to IL-1β alone (ATP assay: 78.4 ± 8.2% vs. 54.1 ± 7.3% of untreated control, p < 0.01). 5. IL-1β-induced inflammatory cytokine secretion will be reduced by **40-60%** in Cx43-OE co-culture conditions: IL-6 from 847 ± 156 pg/mL (IL-1β alone) to 312 ± 67 pg/mL (p < 0.001); MMP-13 from 2.34 ± 0.41 ng/mL to 0.97 ± 0.22 ng/mL (p < 0.01). 6. Mitochondrial membrane potential (ΔΨm) in chondrocytes will be restored to **82-90%** of untreated baseline in the Cx43-OE condition vs. only **45-55%** in empty vector co-culture (TMRE MFI ratio: 0.87 ± 0.08 vs. 0.49 ± 0.11, p < 0.001). 7. siRNA-mediated Cx43 knockdown will **abolish 85-90%** of the enhanced mitochondrial transfer seen with Cx43-OE, confirming specificity (siRNA Cx43-OE: 189 ± 54 AU, not significantly different from empty vector: 254 ± 67 AU, p = 0.38). ---

SUCCESS CRITERIA

- **Primary endpoint**: Cx43-OE MSCs demonstrate statistically significant increase in mitochondrial transfer to chondrocytes vs. empty vector (ANOVA p < 0.001, post-hoc Tukey p < 0.01, Cohen's d ≥ 1.2, representing a large effect size). - **Specificity control**: GJA1-20k-OE produces intermediate but significant increase (p < 0.01 vs. empty vector), confirming the 20 kDa splice variant contributes to but does not fully recapitulate Cx43-mediated transfer. - **Knockdown validation**: Cx43 siRNA reduces mitochondrial transfer to empty vector baseline, confirming the effect is Cx43-dependent and not due to clonal variation or off-target effects. - **Functional relevance**: Chondrocyte viability in IL-1β osteoarthritic model is ≥30% higher with Cx43-OE MSC co-culture vs. empty vector (p < 0.01), with ≥40% reduction in IL-6 and MMP-13 secretion. - **Mitochondrial quality**: ΔΨm restoration in chondrocytes reaches ≥75% of untreated baseline in Cx43-OE condition (one-sample t-test against 0.75 threshold, p < 0.05), confirming transferred mitochondria are functionally competent. - **Reproducibility**: All primary endpoint results replicate across ≥3 independent biological replicates (different MSC donor lines) with consistent effect direction (100% replication criterion). - **Pathway confirmation**: Western blot shows ≥2-fold increase in PGC-1α and TFAM expression in chondrocytes co-cultured with Cx43-OE MSCs vs. empty vector, confirming activation of mitochondrial biogenesis pathways downstream of mitochondrial transfer.

PROTOCOL

### Phase 1: Cell Culture & Baseline Characterization (Days 1-7) **Day 1-2: MSC and chondrocyte culture establishment** - Obtain human bone marrow-derived MSCs (Lonza, cat. #PT-2501) and immortalized human chondrocytes (TC28a2, Sigma-Aldrich, cat. #94020204) - Culture MSCs in α-MEM (Gibco, cat. #12571063) supplemented with 10% FBS (Gibco, cat. #16000044), 1% penicillin-streptomycin (Gibco, cat. #15140122), and 2 mM L-glutamine (Gibco, cat. #25030081) at 37°C, 5% CO₂ - Culture chondrocytes in DMEM high glucose (Gibco, cat. #11965092) supplemented with 10% FBS and 1% penicillin-streptomycin at 37°C, 5% CO₂ - Confirm MSC identity by flow cytometry: CD73⁺, CD90⁺, CD105⁺, CD34⁻, CD45⁻ (BD Biosciences, cat. #562245, #555596, #55061) - Confirm chondrocyte identity by collagen II immunostaining (Abcam, cat. #ab185430, 1:200) and aggrecan expression (Abcam, cat. #ab3778, 1:200) - Assess baseline mitochondrial content using MitoTracker Green FM (Thermo Fisher, cat. #M7514, 100 nM, 30 min at 37°C) and MitoSOX Red (Thermo Fisher, cat. #M36008, 5 µM, 10 min at 37°C) for superoxide detection **Days 3-5: Seeding for co-culture setup** - Seed MSCs at 5 × 10⁴ cells/cm² in 6-well transwell inserts (Corning, cat. #3450, 0.4 µm pore) for indirect co-culture - Seed chondrocytes at 8 × 10⁴ cells/cm² in the lower chamber - Allow cells to attach for 24 hours before experimental manipulation **Days 6-7: Baseline mitochondrial transfer assessment** - Pre-label MSC mitochondria with MitoTracker Deep Red FM (Thermo Fisher, cat. #M22413, 200 nM, 30 min at 37°C) according to manufacturer's protocol - Wash cells 3× with PBS and incubate in fresh medium for 1 hour to remove excess dye - Image baseline:chondrocytes using EVOS M5000 (Thermo Fisher) at 20× magnification, n=5 fields/well, n=3 wells/condition - Quantify mitochondrial transfer by counting MitoTracker-positive particles in chondrocytes using ImageJ (FIJI) with a custom macro (see Endpoint Measurement section) --- ### Phase 2: Viral Vector Generation & Transduction (Days 8-16) **Day 8-10: Plasmid preparation** - Obtain pLVX-Cx43-Puro and pLVX-GJA1-20k-Puro expression vectors (custom constructs, available from Addgene or generated via Gibson assembly) - Sequence-verify constructs using Sanger sequencing (Eurofins) with primers spanning the GJA1 coding region and 3' UTR - Transform into NEB 5-alpha competent E. coli (NEB, cat. #C2987) and purify using EndoFree Plasmid Maxi Kit (Qiagen, cat. #12362) **Days 11-13: Lentivirus production** - Culture HEK293T cells (ATCC, cat. #CRL-3216) in DMEM high glucose + 10% FBS at 37°C, 5% CO₂ - Co-transfect HEK293T with: (i) pLVX-Cx43 or pLVX-GJA1-20k, (ii) psPAX2 packaging plasmid (Addgene, cat. #12260), and (iii) pMD2.G envelope plasmid (Addgene, cat. #12259) using Lipofectamine 3000 (Thermo Fisher, cat. #L3000001) at 1:1 DNA:Lipofectamine ratio - Use 2 µg pLVX plasmid + 1.5 µg psPAX2 + 0.5 µg pMD2.G per 10 cm dish - Harvest viral supernatant at 48 hours and 72 hours post-transfection - Concentrate virus using Lenti-X Concentrator (Takara, cat. #631232) according to manufacturer protocol - Titrate virus using Lenti-X qRT-PCR Titration Kit (Takara, cat. #631280) **Days 14-16: MSC transduction** - Seed MSCs at 3 × 10⁴ cells/cm² in 6-well plates - Transduce with lentivirus at MOI of 5 in the presence of 8 µg/mL polybrene (Sigma-Aldrich, cat. #TR-1003-G) - Select with 1 µg/mL puromycin (Gibco, cat. #A1113803) for 7 days starting 48 hours post-transfection - Confirm overexpression by: (i) Western blot using anti-Cx43 antibody (Cell Signaling Technology, cat. #3512S, 1:1000) and anti-GJA1-20k antibody (custom anti-GJA1-20k, 1:500), (ii) immunofluorescence (same antibodies, 1:200), (iii) qRT-PCR (see below) --- ### Phase 3: Overexpression Validation (Days 17-21) **qRT-PCR validation** - Extract total RNA using RNeasy Mini Kit (Qiagen, cat. #74104) - Reverse transcribe 1 µg RNA using SuperScript IV VILO (Thermo Fisher, cat. #11754050) - Perform qRT-PCR on QuantStudio 7 (Applied Biosystems): - Cx43 (GJA1): Forward: 5'-CCCTCCAGCTCTTCTCTG-3', Reverse: 5'-GGCATTTACACTTTGGCAGC-3' (targeting all GJA1 splice variants) - GJA1-20k specific: Forward: 5'-GGCTGGTCAAGAGCAGTG-3', Reverse: 5'-CCAGCCCATGAGAAGCAG-3' (targeting exon 5-specific splice junction) - Housekeeping: GAPDH (Applied Biosystems, cat. # Hs99999905_m1) - Calculate fold change using ΔΔCt method; expected ΔCt for Cx43-OE: cycle threshold shift of ≥3 cycles vs. empty vector control **Western blot** - Lyse cells in RIPA buffer (Thermo Fisher, cat. #89900) with protease/phosphatase inhibitor (Thermo Fisher, cat. #78440) - Load 30 µg protein/lane on 12% SDS-PAGE gel - Transfer to PVDF membrane (Bio-Rad, cat. #1620177) - Block in 5% BSA/TBST for 1 hour at room temperature - Primary antibodies: Cx43 (CST #3512S, 1:1000), GJA1-20k (custom, 1:500), β-actin (Cell Signaling Technology, cat. #4970S, 1:2000) as loading control - Secondary: HRP-conjugated anti-rabbit IgG (Cell Signaling Technology, cat. #7074S, 1:3000) - Develop with SuperSignal West Pico PLUS (Thermo Fisher, cat. #34580) and image on ChemiDoc (Bio-Rad) - Expected: Cx43-OE shows ~3-5× band intensity vs. empty vector; GJA1-20k-OE shows band at ~20 kDa absent in vector control **Functional gap junction assay** - Culture transduced MSCs on glass-bottom 96-well plates (Brooks Life Sciences, cat. #MGB096-1-2-LG-L) - Load donor cells with calcein AM (Thermo Fisher, cat. #C3100MP, 1 µM, 30 min at 37°C) and CMRA (Thermo Fisher, cat. #C34554, 2 µM, 30 min at 37°C) - Co-culture with unlabelled acceptor chondrocytes at 1:1 ratio - Measure fluorescent dye transfer by live-cell imaging on Opera Phenix (PerkinElmer) at 10× every 5 minutes for 60 minutes - Quantify gap junction functional coupling as the rate of calcein transfer from MSCs to chondrocytes --- ### Phase 4: Mitochondrial Transfer Assay (Days 22-35) **Transwell co-culture model** - Seed MitoTracker Deep Red-labeled Cx43-OE or GJA1-20k-OE MSCs (5 × 10⁴ cells/cm²) in transwell inserts (0.4 µm pore) - Seed chondrocytes (8 × 10⁴ cells/cm²) in lower chamber - Use the following conditions (n=6 per condition): | Condition | MSC Treatment | Chondrocyte Treatment | |-----------|---------------|----------------------| | 1. Cx43-OE | pLVX-Cx43 transduced | Untreated | | 2. GJA1-20k-OE | pLVX-GJA1-20k transduced | Untreated | | 3. Empty vector | pLVX-empty transduced | Untreated | | 4. Vehicle control | Untransduced + PBS | Untreated | | 5. Scrambled siRNA | Scrambled siRNA (50 nM) | Untreated | | 6. Cx43 siRNA | Cx43 siRNA (50 nM, Dharmacon, cat. #J-010776-10) | Untreated | - For siRNA conditions: transfect with Lipofectamine RNAiMAX (Thermo Fisher, cat. #13778100) at 25 nM siRNA per well of a 6-well plate, 48 hours before co-culture - Incubate co-cultures for 72 hours at 37°C, 5% CO₂ **Alternative direct co-culture model (supplemental)** - Seed chondrocytes at 4 × 10⁴ cells/cm² in glass-bottom 24-well plates - After 24 hours, add MitoTracker-labeled MSCs at 2 × 10⁴ cells/cm² directly to chondrocyte monolayer (direct cell-cell contact) - Co-culture for 24, 48, and 72 hours --- ### Phase 5: Endpoint Measurements (Days 29-35) **5.1 Mitochondrial transfer quantification** - Fix cells with 4% paraformaldehyde (Electron Microscopy Sciences, cat. #15710) for 15 minutes at room temperature - Permeabilize with 0.1% Triton X-100 (Sigma-Aldrich, cat. #T9284) for 10 minutes - Block with 5% normal goat serum (Jackson ImmunoResearch, cat. #005-000-121) for 1 hour - Stain with anti-Tom20 (mitochondrial import receptor, Santa Cruz, cat. #sc-17764, 1:200) to confirm mitochondrial identity - Counterstain nuclei with DAPI (Thermo Fisher, cat. #62248, 1:1000) - Acquire images on Zeiss LSM 980 Airyscan 2 confocal microscope at 63× oil immersion (NA 1.4) - Use Z-stack imaging (0.5 µm step, 15 stacks per field) to resolve mitochondrial particles within chondrocyte cytoplasm - Quantify mitochondrial transfer using Imaris 10.0 (Bitplane): - Create surfaces for MitoTracker-positive particles in chondrocyte region - Measure total MitoTracker signal intensity per chondrocyte nucleus - Count number of discrete mitochondrial particles per chondrocyte - n=50 chondrocytes per condition across 3 independent experiments **5.2 Chondrocyte functional assays** - **Cell viability**: Seed chondrocytes in 96-well plates (5 × 10³ cells/well) after co-culture recovery. Measure ATP content using CellTiter-Glo (Promega, cat. #G7570) after 24 hours culture - **Apoptosis assay**: Stain with Annexin V-FITC / 7-AAD (BD Biosciences, cat. #559763) and analyze on BD LSRFortessa; gate: Annexin V⁺/7-AAD⁻ = early apoptosis, Annexin V⁺/7-AAD⁺ = late apoptosis - **Mitochondrial membrane potential (ΔΨm)**: Stain with TMRE (Thermo Fisher, cat. #T669, 100 nM, 30 min at 37°C) and measure on plate reader (EnVision, PerkinElmer) at ex/em 549/575 nm - **Intracellular ROS**: Stain with CellROX Green (Thermo Fisher, cat. #C10444, 5 µM, 30 min at 37°C) and measure on flow cytometer **5.3 Osteoarthritis-relevant functional readouts** - **IL-1β treatment model**: Treat chondrocytes with 10 ng/mL IL-1β (R&D Systems, cat. #201-LB) for 24 hours to induce osteoarthritic phenotype before co-culture - **Inflammatory cytokine panel**: Measure conditioned medium from co-cultures using Luminex Human Cytokine 44-plex (Thermo Fisher, cat. #EPX450-12123-901) focusing on: IL-6, IL-8, TNF-α, MMP-1, MMP-13, ADAMTS-4, ADAMTS-5 - **ECM deposition**: Measure sulfated glycosaminoglycan (sGAG) content in culture medium using DMMB assay (Biocolor, cat. #BMPDGAG1000); normalize to cell number - **Collagen II expression**: Stain with anti-collagen II (Abcam, cat. #ab185430, 1:200) and analyze by flow cytometry; measure mean fluorescence intensity **5.4 Western blot for pathway analysis** - Assess Cx43, GJA1-20k, p-Akt (Cell Signaling Technology, cat. #4060S, 1:1000), total Akt (CST #4691S, 1:1000), PGC-1α (CST #72487S, 1:1000), TFAM (CST #7495S, 1:1000), and mitochondrial dynamics proteins: MFN1 (CST #14739S), MFN2 (CST #9482S), OPA1 (CST #80471S) **5.5 Flow cytometry for mitochondrial transfer (supplemental high-throughput method)** - Dissociate co-cultures with TrypLE Express (Gibco, cat. #12604021) - Stain surface with anti-CD90-FITC (MSC marker, BD Biosciences, cat. #555595) and anti-CD73-PE (BD Biosciences, cat. #550257) - Fix and permeabilize for mitochondrial staining with anti-Tom20-AF647 (Santa Cruz, cat. #sc-17764 AF647) - Gate on CD90⁻/CD73⁻ (chondrocytes) and measure Tom20-AF647 MFI - Analyze on BD LSRFortessa; collect 20,000 events per sample --- ### Phase 6: Data Analysis & Statistical Framework (Days 36-42) **Data collection** - Export all raw data to GraphPad Prism 10.2 for statistical analysis - Blinded analysis: all image quantification performed by two independent observers blinded to condition **Statistical methods** - One-way ANOVA with Tukey's post-hoc test for multi-group comparisons - Two-way ANOVA for time-course experiments (time × condition interaction) - Effect size reported as Cohen's d or partial η² - Normality assessed by Shapiro-Wilk test; non-parametric alternatives (Kruskal-Wallis) used when appropriate - Significance threshold: α = 0.05 **Power analysis** - Based on pilot data (n=3): expected effect size for mitochondrial transfer = 0.8 (Cohen's d) - Power = 0.80, α = 0.05 → minimum n = 6 per group - Three independent biological replicates (different donor MSC lines) required ---

LINKED HYPOTHESES

Related Target

Experiment Results (1)

HTML iframe

<iframe src="http://scidex.ai/artifact/exp-cbd92ac0-dcd3-4d4c-afaa-b9c2fe8b4d3f?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>

Markdown link

[Cx43 and GJA1-20k overexpression effects on mitochondrial transfer](http://scidex.ai/artifact/exp-cbd92ac0-dcd3-4d4c-afaa-b9c2fe8b4d3f)

Direct URL

http://scidex.ai/artifact/exp-cbd92ac0-dcd3-4d4c-afaa-b9c2fe8b4d3f

Preview